‘GVHD’: Graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning

Bone Marrow Transplantation

Volumn 31, Issue 9, 2003, Pages 739-746

  Porter, D L ^a   Stadtmauer, E A ^a   Lazarus, H M ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Allogeneic stem cell transplantation; Graft versus lymphoma; Hodgkin s disease

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; FLUDARABINE; GANCICLOVIR; MELPHALAN; THIOTEPA;

ADOPTIVE IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; FEASIBILITY STUDY; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; PRIORITY JOURNAL; SAFETY; SHORT SURVEY; STEM CELL; T LYMPHOCYTE;

GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOCYTE TRANSFUSION;

EID: 0038751726     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703895     Document Type: Article

References (81)

1. Mathe G, Amiel J, Schwarzenberg L et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965; 25: 1525-1531.
2. Barnes D, Corp M, Loutit J, Neal F. Treatment of murine leukaemia with X rays and homologous bone marrow. Preliminary communication. Br Med J 1956; 2: 626-630.
3. Sykes M, Romick M, Sachs D. Interleukin 2 prevents graftversus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990; 87: 5633-5637.
4. Truitt R, LeFever A, Shih C-Y. Graft-versus-leukemia reactions: experimental models and clinical trails. In: Gale R, Champlin R, eds. Progress in Bone Marrow Transplantation. Alan R Liss: New York, 1987, pp 219-232.
5. Slavin S, Weiss L, Morecki S, Weigenberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155-159.
6. Collins R, Rogers Z, Bennett M et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391-395.
7. Odom L, August C, Githens J et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versusleukaemia reaction' in man? Lancet. 1978; 2: 537-540.
8. Horowitz M, Gale R, Sondel P et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
9. Gale R, Horowitz M, Ash R et al. Identical-twin bone marrow transplants for leukemia. Ann Int Med 1994; 120: 646-652.
10. Weiden P, Sullivan K, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
11. Apperley J, Mauro F, Goldman J et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988; 69: 239-245.
12. Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76: 2462-2465.
13. Kolb H, Schattenberg A, Goldman J et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
14. Porter D, Roth M, McGarigle C et al. Induction of graftversus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
15. Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
16. Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive Immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995; 15: 591-594.
17. Drobyski W, Keever C, Roth M et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
18. Porter D, Collins R, Shpilberg O et al. Long term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood and Marrow Transplant 1999; 5: 253-261.
19. Dazzi F, Szydlo RM, Cross NC et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
20. Shimoni A, Gajewski J, Donato M et al. Long-term follow-up of recipients of CD8 depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2001; 7: 568-575.
21. Collins Jr, RH, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
22. Levine J, Braun T, Penza S et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation. J Clin Oncol 2001; 20: 405-412.
23. Jones R, Ambinder R, Piantadosi S et al. Evidence of a graftversus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
24. Akpek G, Ambinder R, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.
25. Anderson J, Litzow M, Appelbaum F et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
26. Peniket A, Ruiz de Elvira M, Taghipour G et al. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality. Blood 1997; 90: 255a.
27. Milpied N, Fielding A, Pearce R et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14: 1291-1296.
28. Appelbaum FR, Sullivan KM, Thomas ED et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J Clin Oncol 1985; 3: 1490-1494.
29. Phillips GL, Reece DE, Barnett MJ et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 1989; 7: 1039-1045.
30. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
31. Porter D, Connors J, VanDeerlin V et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999; 17: 1234-1243.
32. Khouri I, Keating M, Korbling M et al. Transplant-lite: induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
33. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
34. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
35. Porter D, Luger S, Duffy K et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 230-238.
36. Anderlini P, Giralt S, Andersson B et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
37. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
38. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus-tumor effects. Blood 2001; 97: 3390-3400.
39. Spitzer T, McAfee S, Sackstein R et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLAmatched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
40. Dey B, McAfee S, Sackstein R et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplant. Biol Blood Marrow Transplant 2001; 7: 604-612.
41. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
42. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
43. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
44. Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75-82.
45. Bornhauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin (In Process Citation). Bone Marrow Transplant 2000; 26: 119-125 (MEDLINE record in process).
46. Radich J, Gooley T, Snaders J et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272-279.
47. Vose J, Bierman P, Anderson J et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
48. Chiang K, Weisdorf D, Davies S et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant disease. Bone Marrow Transplant 1996; 17: 39-42.
49. Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
50. Dazzi F, Szydlo RM, Craddock C et al. Comparison of singledose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
51. Alyea E, Soiffer R, Canning C et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671-3680.
52. Giralt S, Hester J, Huh Y et al. CD8-deplete d donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
53. Waller EK, Boyer M. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplant 2000; 25: S20-S24.
54. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
55. Fowler DH, Kurasawa K, Smith R et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-3549.
56. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
57. Hill GR, Cooke KR, Teshima T et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102: 115-123.
58. Panoskaltsis-Mortari A, Taylor PA, Rubin JS et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96: 4350-4356.
59. Porter D, Bunin N, Laport G et al. Graft-vs-tumor induction with donor leukocyte infusions expanded ex vivo by activation with CD3/CD28 costimulation. Blood 2001; 98: 404a.
60. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia. Science 1997; 276: 1719-1724.
61. Servida P, Rossini S, Traversari C et al. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBVinduced lymphoma. Blood 1993; 82: 214a.
62. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179-3187.
63. Gahn B, Siller-Lopez F, Pirooz AD et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001; 93: 706-713.
64. Papadopoulos E, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
65. Porter D, Orloff G, Antin J. Do nor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 1994; 4: 11-15.
66. Small T, Papadopoulos E, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-celldepleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467-480.
67. Rooney C, Smith C, Ng C et al. Infusion of cytoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
68. Roskrow M, Suzuki N, Gan Y et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998; 91: 2925-2934.
69. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood 1996; 87: 3587-3592.
70. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
71. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
72. Mutis T, Gillespie G, Schrama E et al. Tetrameric HLA class Iminor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999; 5: 839-842.
73. Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117: 935-939.
74. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic systemrestricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
75. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-1020.
76. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
77. Mandigers CM, Raemaekers JM, Schattenberg AV et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. British Journal of Haematology 1998; 100: 198-206.
78. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
79. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037.
80. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184.
81. Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19: 3340-3349.